Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Financials are out on Sedar
View:
Post by Pandora on Jul 20, 2021 12:47am

Financials are out on Sedar

Anyone care to take a look? Take your mind off the current subject.
Comment by Oden6570 on Jul 20, 2021 7:03am
Quarter 2 ?
Comment by Eoganacht on Jul 20, 2021 9:57am
Looks like they refiled Quarter 1.
Comment by enriquesuave on Jul 20, 2021 10:07am
Yes that's Q1 and results look amazing to me. So far 7 patients out of 22 are CR at both 3 months and maintained at 6 months.( that's 2 from PH1 and 5 from PH2)..  Also 2 PR or partial responses are still PR at 6 months ( indicating they have a clean cystoscope exam and only urine cytology is positive), which is also amazing as there is a good chance that they have UUTUC rather than ...more  
Comment by StevenBirch on Jul 20, 2021 10:22am
Thanks for the recap Enriquesuave.
Comment by stocksnbonds458 on Jul 20, 2021 10:43am
Agreed Enrique, if further results trickle in as expected our averages should increase such that they will improve CR %'s and thus reduce the impact of the skewed numbers attributed to the botched start to this phase 2 trial.
Comment by Rumpl3StiltSkin on Jul 20, 2021 4:31pm
Great news Gents! Glad to see this happening finally. Good luck to all!
Comment by Eoganacht on Jul 20, 2021 11:45am
Awesome! And the FDA criterion for accelerated approval of drugs for serious conditions that fill an unmet medical need are quite liberal: "Using surrogate or intermediate clinical endpoints can save valuable time in the drug approval process. For example, instead of having to wait to learn if a drug actually extends survival for cancer patients, the FDA may approve a drug based on evidence ...more  
Comment by 99942Apophis on Jul 20, 2021 1:45pm
Eoganacht wrote Awesome! And the FDA criterion for accelerated approval of drugs for serious conditions that fill an unmet medical need are quite liberal: "Using surrogate or intermediate clinical endpoints can save valuable time in the drug approval process. For example, instead of having to wait to learn if a drug actually extends survival for cancer patients, the FDA may approve a drug ...more  
Comment by 2b7f6fab on Jul 21, 2021 1:39am
well i think egonuts has me on ignore from a few years ago, however i read everything he posts on this board.  and i read everything vestor says on the other board.  and basically everything anyone elses posted here or there.  bought my first 100 thousand shares about 8 years ago and averaged down since then,  put em up for sale if you have em btchs, you only live once.
Comment by Oden6570 on Jul 20, 2021 1:46pm
Thank you for sharing the light !
Comment by CancerSlayer on Jul 20, 2021 10:21pm
  Nice summary Enrique... My eyes are now laser-focused on optimized patients only at this point...the protocol recommended for community practice.  I would add that under "optimized" treatment conditions (including patients 5 & 6 from Ph 1), we are currently looking at the following post 90 day assessments: CR = 4 patients No R = 1 patient (? patient death due to ...more  
Comment by riverrrow on Jul 20, 2021 9:19am
As usual, updated trial results look muddled. I hope I'm misinterpreting but it looks to me even with proper dosing the cure rate is still only 30 to 40%. I was expecting closer to 100%. GLTA.
Comment by socksnblonds642 on Jul 20, 2021 9:36am
I don't think anything has changed news wise hence no change in the results. They can't make up CR numbers for a Q2 financial. We simply have to wait for the results. Does it say how much money is left or how the trials are progressing etc? That would be interesting.
Comment by 99942Apophis on Jul 20, 2021 10:02am
socksnblonds642 wrote I don't think anything has changed news wise hence no change in the results. They can't make up CR numbers for a Q2 financial. We simply have to wait for the results. Does it say how much money is left or how the trials are progressing etc? That would be interesting. Thats accurate socksnblonds642, the 2nd quarter financials are a report on activity for the 3 month ...more  
Comment by yambego on Jul 20, 2021 9:37am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250